TXN promotes tumorigenesis by activating the ERK1/2 and ERK5 signaling pathways regulating c-Myc in non-small cell lung cancer

被引:0
作者
Liu, Xiaoting [1 ]
Dong, Xilin [1 ]
Hu, Yifan [1 ]
Dong, Cong [2 ]
Wu, Sanzhu [3 ]
Fang, Yanan [1 ]
Hu, Yaxin [1 ]
机构
[1] Xi An Jiao Tong Univ, Affiliated Hosp 2, Dept Resp, 157 Xiwu Rd, Xian 710004, Shaanxi, Peoples R China
[2] Xi An Jiao Tong Univ, Affiliated Hosp 2, Dept Rehabil, 157 Xiwu Rd, Xian 710004, Shaanxi, Peoples R China
[3] Xian Shiyou Univ, Sch Comp Sci, 18,East Sect,Elect Second Rd, Xian 710065, Shaanxi, Peoples R China
关键词
TXN; ERKs; C-Myc; NSCLC; Tumorigenesis; THIOREDOXIN; SUPPRESSION; INHIBITORS; MELANOMA;
D O I
10.1016/j.cellsig.2024.111517
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Lung cancer is the primary cause of cancer-related deaths worldwide, particularly for non-small cell lung cancer (NSCLC). However, the exact mechanism underlying tumor formation remains unclear. It is widely acknowledged that inflammation and oxidative stress occur in the tumor microenvironment, promoting cell malignant growth and metastasis. Thioredoxin-1 (TXN), the main regulator of oxidative stress, plays a significant role in the development of NSCLC. However, the specific tumor-promoting mechanism is still being investigated. This study aimed to examine the function and mechanism of TXN in NSCLC. The effects of knockdown or overexpression TXN on cell proliferation, invasion and apoptosis were evaluated by Cell Counting Kit-8, colony formation, wound healing, transwell, TUNEL staining, and flow cytometric assays. Western blotting was performed to analyze the regulation of TXN and downstream proteins suppressed by genes and pharmacology. TXN knockdown significantly suppressed cell proliferation, invasion and promoted apoptosis both in vitro and in vivo, whereas TXN overexpression reversed these malignant phenotypes. We found that TXN regulated c-Myc expression through ERK1/2 and ERK5 signaling pathways. Suppressing ERK1/2 led to the compensatory activation of ERK5, and simultaneously inhibiting ERK1/2 and ERK5 synergistically reduced c-Myc expression, further attenuating cell proliferation, invasion and enhanced apoptosis. Our results indicated tumor promotion of TXN in NSCLC and TXN regulated c-Myc in the interest of tumorigenesis through ERK1/2 and ERK5 signaling pathways. Targeting TXN and blocking the ERK1/2 and ERK5 pathways could potentially offer new therapeutic strategies for NSCLC.
引用
收藏
页数:15
相关论文
共 37 条
  • [1] Efficient Suppression of NRAS-Driven Melanoma by Co-Inhibition of ERK1/2 and ERK5 MAPK Pathways
    Adam, Christian
    Fusi, Lorenza
    Weiss, Neele
    Goller, Simon G.
    Meder, Katharina
    Frings, Verena G.
    Kneitz, Hermann
    Goebeler, Matthias
    Houben, Roland
    Schrama, David
    Schmidt, Marc
    [J]. JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2020, 140 (12) : 2455 - +
  • [2] Resistance to MAPK Inhibitors in Melanoma Involves Activation of the IGF1R-MEK5-Erk5 Pathway
    Benito-Jardon, Lucia
    Diaz-Martinez, Marta
    Arellano-Sanchez, Nohemi
    Vaquero-Morales, Paloma
    Esparis-Ogando, Azucena
    Teixido, Joaquin
    [J]. CANCER RESEARCH, 2019, 79 (09) : 2244 - 2256
  • [3] Diverse and converging roles of ERK1/2 and ERK5 pathways on mesenchymal to epithelial transition in breast cancer
    Bhatt, Akshita B.
    Wright, Thomas D.
    Barnes, Van
    Chakrabarty, Suravi
    Matossian, Margarite D.
    Lexner, Erin
    Ucar, Deniz A.
    Miele, Lucio
    Flaherty, Patrick T.
    Burow, Matthew E.
    Cavanaugh, Jane E.
    [J]. TRANSLATIONAL ONCOLOGY, 2021, 14 (06):
  • [4] A Comprehensive Review on MAPK: A Promising Therapeutic Target in Cancer
    Braicu, Cornelia
    Buse, Mihail
    Busuioc, Constantin
    Drula, Rares
    Gulei, Diana
    Raduly, Lajos
    Rusu, Alexandru
    Irimie, Alexandru
    Atanasov, Atanas G.
    Slaby, Ondrej
    Ionescu, Calin
    Berindan-Neagoe, Ioana
    [J]. CANCERS, 2019, 11 (10)
  • [5] ERK5 Signalling and Resistance to ERK1/2 Pathway Therapeutics: The Path Less Travelled?
    Cook, Simon J.
    Lochhead, Pamela A.
    [J]. FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY, 2022, 10
  • [6] MYC: a complex problem
    Das, Subhendu K.
    Lewis, Brian A.
    Levens, David
    [J]. TRENDS IN CELL BIOLOGY, 2023, 33 (03) : 235 - 246
  • [7] ERK5 signalling rescues intestinal epithelial turnover and tumour cell proliferation upon ERK1/2 abrogation
    de Jong, Petrus R.
    Taniguchi, Koji
    Harris, Alexandra R.
    Bertin, Samuel
    Takahashi, Naoki
    Duong, Jen
    Campos, Alejandro D.
    Powis, Garth
    Corr, Maripat
    Karin, Michael
    Raz, Eyal
    [J]. NATURE COMMUNICATIONS, 2016, 7
  • [8] The MYC oncogene - the grand orchestrator of cancer growth and immune evasion
    Dhanasekaran, Renumathy
    Deutzmann, Anja
    Mahauad-Fernandez, Wadie D.
    Hansen, Aida S.
    Gouw, Arvin M.
    Felsher, Dean W.
    [J]. NATURE REVIEWS CLINICAL ONCOLOGY, 2021, 19 (1) : 23 - 36
  • [9] A CRISPR screen identifies MAPK7 as a target for combination with MEK inhibition in KRAS mutant NSCLC
    Dompe, Nicholas
    Klijn, Christiaan
    Watson, Sara A.
    Leng, Katherine
    Port, Jenna
    Cuellar, Trinna
    Watanabe, Colin
    Haley, Benjamin
    Neve, Richard
    Evangelista, Marie
    Stokoe, David
    [J]. PLOS ONE, 2018, 13 (06):
  • [10] The Thioredoxin System: A Promising Target for Cancer Drug Development
    Ghareeb, Hiba
    Metanis, Norman
    [J]. CHEMISTRY-A EUROPEAN JOURNAL, 2020, 26 (45) : 10175 - 10184